Correction of the Biochemical and Functional Deficits in Fabry Mice Following AAV8–mediated Hepatic Expression of α-galactosidase A
Molecular Therapy2006Vol. 15(3), pp. 492–500
Citations Over TimeTop 10% of 2006 papers
Robin J. Ziegler, Maribeth Cherry, Christine M. Barbon, Chester Li, Scott D. Bercury, Donna Armentano, Robert J. Desnick, Seng H. Cheng
Related Papers
- → Coformulation of a Novel Human α -Galactosidase A With the Pharmacological Chaperone AT1001 Leads to Improved Substrate Reduction in Fabry Mice(2015)36 cited
- → Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease(2016)13 cited
- → Enzyme replacement therapy for Fabry disease: Morphologic and histochemical changes in the urinary sediments(2005)21 cited
- → MiRNA Let-7a and Let-7d Are Induced by Globotriaosylceramide via NF-kB Activation in Fabry Disease(2021)8 cited
- → Enzyme Replacement Therapy in Patients with Fabry's Disease(2007)12 cited